| 1 |
国家卫生健康委加强脑卒中防治工作减少百万新发残疾工程专家委员会, 吉训明. 《2024年中国脑卒中防治报告》概要[J]. 首都医科大学学报, 2025, 46(6): 947-960.
|
| 2 |
Jiang Y, Wang G, Jiang S, et al. Molecular mechanisms and targeted intervention strategies of calcium overload in ischemic stroke[J]. Int J Mol Sci, 2026, 27(5): 2279.
|
| 3 |
中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2023[J]. 中华神经科杂志, 2024, 57(6): 523-559.
|
| 4 |
霍晓川, 高峰. 急性缺血性卒中血管内治疗中国指南2023[J]. 中国卒中杂志, 2023, 18(6): 684-711.
|
| 5 |
Deng G, Chu YH, Xiao J, et al. Risk factors, pathophysiologic mechanisms, and potential treatment strategies of futile recanalization after endovascular therapy in acute ischemic stroke[J]. Aging Dis, 2023, 14(6): 2096-2112.
|
| 6 |
Pereira da Silva AM, Ribeiro Gonçalves O, Falcão L, et al. Association between the no-reflow phenomenon and clinical outcomes after endovascular treatment for acute ischemic stroke: a systematic review and Meta-analysis[J]. Eur Stroke J, 2026, 11(1): 23969873251376846.
|
| 7 |
Xu L, Gao Y, Hu M, et al. Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2/HO-1 signaling pathway in mice[J]. Fundam Clin Pharmacol, 2022, 36(5): 790-800.
|
| 8 |
Xu J, Wang A, Meng X, et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase Ⅲ, randomized, double-blind, comparative trial[J]. Stroke, 2021, 52(3): 772-780.
|
| 9 |
冯洁, 刘泽宇, 樊屹殊. 缺血性卒中脑细胞保护临床实践中国专家共识[J]. 国际神经病学神经外科学杂志, 2025, 52(2): 1-7.
|
| 10 |
Yamashita T, Abe K. Update on antioxidant therapy with edaravone: expanding applications in neurodegenerative diseases[J]. Int J Mol Sci, 2024, 25(5): 2945.
|
| 11 |
周文, 赵秀丽. 依达拉奉右莰醇在缺血性脑卒中的研究进展[J]. 临床医学进展, 2023, 13(6): 9947-9951.
|
| 12 |
符元号, 张晓娜, 谢忱忱. 依达拉奉在经颅内血肿微创引流术后硬膜外血肿患者中的应用[J]. 药学进展, 2025, 49(8): 698-702.
|
| 13 |
Chen Z, Li T, Tang HB, et al. Edaravone dexborneol provides neuroprotective effect by inhibiting neurotoxic activation of astrocytes through inhibiting NF-κB signaling in cortical ischemia[J]. Brain Res Bull, 2024, 218: 111097.
|
| 14 |
Hu R, Liang J, Ding L, et al. Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke[J]. Int Immunopharmacol, 2022, 113(Pt A): 109315.
|
| 15 |
Rahmati-Dehkordi F, Khanifar H, Zare-Hoseinabadi A, et al. Potential of edaravone dexborneol in the treatment of cerebral ischemia: focus on cell death-related signaling pathways[J]. Mol Biol Rep, 2024, 51(1): 1007.
|
| 16 |
Zhang H, Cao R, Chen W, et al. Abstract WP21: the novel target and mechanism of clinically used edaravone dexborneol for ischemic stroke in China[J]. Stroke, 2025, 56(Suppl_1): AWP21-AWP21.
|
| 17 |
杨晨昕, 李伟. 炎症指标在脑卒中诊疗中的关键作用及研究新进展[J]. 临床个性化医学, 2025, 4(3): 585-598.
|
| 18 |
Wang X, Liu JJ, Zheng XR, et al. (+)-Borneol enhances the protective effect of edaravone against cerebral ischemia/reperfusion injury by targeting OAT3/P-gp transporters for drug delivery into the brain[J]. Phytomedicine, 2025, 139: 156521.
|
| 19 |
Prabhakaran S, Gonzalez NR, Zachrison KS, et al. 2026 guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke, 2026-01-26 (2026-07-01).
|
| 20 |
Wu HY, Tang Y, Gao LY, et al. The synergetic effect of edaravone and borneol in the rat model of ischemic stroke[J]. Eur J Pharmacol, 2014, 740: 522-531.
|
| 21 |
Xu J, Wang Y, Wang A, et al. Safety and efficacy of edaravone dexborneol versus edaravone for patients with acute ischaemic stroke: a phase Ⅱ, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial[J]. Stroke Vasc Neurol, 2019, 4(3): 109-114.
|
| 22 |
Fu Y, Wang A, Tang R, et al. Sublingual edaravone dexborneol for the treatment of acute ischemic stroke: the TASTE-SL randomized clinical trial[J]. JAMA Neurol, 2024, 81(4): 319-326.
|
| 23 |
Ma G, Mo R, Yao X, et al. Clinical and safety outcomes of edaravone dexborneol in acute ischemic stroke: a multicenter, prospective, cohort study[J]. Neurology, 2025, 105(4): e213949.
|
| 24 |
吴伟杰, 孙紫徽, 徐良额, 等. 依达拉奉右莰醇联合阿替普酶治疗急性缺血性脑卒中疗效的随机对照试验[J]. 药物流行病学杂志, 2024, 33(9): 978-985.
|
| 25 |
Chen HS, Zhao ZA, Shen XY, et al. Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase Ⅱ trial[J]. Nat Commun, 2025, 16(1): 2393.
|
| 26 |
Wang C, Gu H, Huo X, et al. Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial[J]. BMJ, 2026, 392: e086850.
|
| 27 |
李一才, 韩国胜, 窦寿坦, 等. 依达拉奉右莰醇联合丁苯酞注射液治疗急性进展性脑梗死患者的临床研究[J]. 中国临床药理学杂志, 2023, 39(6): 763-767.
|
| 28 |
张红梅, 陈燕. 银杏叶提取物注射液联合依达拉奉右莰醇治疗急性脑梗死的效果及对患者神经功能的影响[J]. 临床医学, 2024, 44(1): 117-120.
|
| 29 |
Wang A, Jia B, Zhang X, et al. Efficacy and safety of butylphthalide in patients with acute ischemic stroke: a randomized clinical trial[J]. JAMA Neurol, 2023, 80(8): 851-859.
|
| 30 |
Dávalos A, Alvarez-Sabín J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)[J]. Lancet, 2012, 380(9839): 349-357.
|
| 31 |
刘旭, 拜承萍. 急性缺血性脑卒中侧支循环影响因素的研究进展[J]. 临床医学进展, 2022, 12(10): 9576-9581.
|
| 32 |
杨丽娟, 武佳芳. 椎动脉发育不良与急性后循环缺血性脑卒中[J]. 中华老年心脑血管病杂志, 2018, 20(1):75-77.
|
| 33 |
Meng S, Tan Q, Guo J, et al. Beyond anterior circulation: clinical outcomes of edaravone dexborneol in posterior circulation stroke[J]. J Stroke Cerebrovasc Dis, 2026, 35(9): 108703.
|
| 34 |
Ma G, Raynald, Arham A, et al. Edaravone dexborneol in large ischemic stroke: real-world experience from a multicenter study in China[J]. J Am Heart Assoc, 2026, 15(1): e044296.
|
| 35 |
克地尔牙·马合木提, 胡波, 杨琼, 等. 依达拉奉右莰醇对急性脑梗死后认知功能障碍的疗效观察[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(5): 459-466.
|